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Abstract
Background: The etiologies of conjugated hyperbilirubinemia in infancy are diverse.
Objective: Determine the prevalence rates of the specific etiologies of conjugated hyperbilirubinemia in infancy.
Data sources: EMBASE and Pubmed were searched electronically and the bibliographies of selected studies were
search manually. The search was conducted independently by two authors.
Study selection: (1) prospective or retrospective case series or cohort study with 10 or more subjects; (2)
consecutive infants who presented with conjugated hyperbilirubinemia; (3) subjects underwent appropriate
diagnostic work-up for conjugated hyperbilirubinemia; (4) no specific diagnoses were excluded in the studied
cohort.
Data extraction: Patient number, age range, country of origin, and categorical and specific etiologies.
Results: From 237 studies identified, 17 studies encompassing 1692 infants were selected. Idiopathic neonatal
hepatitis (INH) occurred in 26.0 % of cases; the most common specific etiologies were extrahepatic biliary atresia
(EHBA) (25.89 %), infection (11.47 %), TPN- associated cholestasis (6.44 %), metabolic disease (4.37 %), alpha-1
anti-trypsin deficiency (4.14 %), and perinatal hypoxia/ischemia (3.66 %). CMV was the most common infection
identified (31.51 %) and galactosemia (36.49 %) was the most common metabolic disease identified.
Limitations: Major limitations are: (1) inconsistencies in the diagnostic evaluations among the different studies and
(2) variations among the sample populations.
Conclusions: INH is the most common diagnosis for conjugated hyperbilirubinemia in infancy while EHBA and
infection are the most commonly identified etiologies. The present review is intended to be a guide to the
differential diagnosis and evaluation of the infant presenting with conjugated hyperbilirubinemia.
Keywords: Conjugated hyperbilirubinemia, Cholestatic jaundice, Newborn, Differential diagnosis
Background
In the newborn period and in early infancy, cholestatic
jaundice, or conjugated hyperbilirubinemia, results from
hepatobiliary dysfunction. The prevalence of this dis-
order is estimated at 1 out of every 2500 live births; ex-
trahepatic biliary atresia (EHBA) and idiopathic neonatal
hepatitis (INH) account for two thirds of cases of infantile
cholestatic jaundice [1].
Most studies of infantile cholestatic jaundice focus
on EHBA. Although this disorder is rare (estimated in-
cidence of 1:15,000 live births), timely diagnosis and
surgical intervention are required to avoid liver failure
and death [1].
Excluding EHBA and INH, a myriad of potential eti-
ologies for infantile cholestatic jaundice have been iden-
tified; these can be categorized into obstructive and
intrinsic processes. Obstruction can be grossly structural or
microscopic in nature (e.g., stones, plugs, or sclerosis of the
biliary tract). Intrinsic processes affect hepatic cellular func-
tion (e.g. infections, metabolic disorders, endocrinopathies,
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chromosomal abnormalities, vascular abnormalities, toxins,
neoplasms, and prematurity) [2]. Given the absence of
large, comprehensive patient series that define the
spectrum and relative incidence of the etiologies of
cholestasis in the newborn period and early infancy,
this systematic review was undertaken.
Methods
Ethics
This study involved the use of published, summary data
from the world’s literature. There was no contact with
primary, patient- identified, source data. Temple Univer-
sity's Human Research Protection Program has declared
that evaluations of publically available, secondary data-
bases of de-identified patient data are not subject to its
review.
Protocol
This study followed the PRISMA guidelines [3].
Eligibility criteria
The study protocol was developed by the authors a
priori. The inclusion criteria for this review were:
(1)prospective or retrospective case series or cohort
study with 10 or more subjects;
(2)consecutive infants who presented with conjugated
hyperbilirubinemia defined as elevations of total and
direct serum bilirubin concentrations beyond the
immediate newborn period;
(3)appropriate diagnostic work-up for conjugated
hyperbilirubinemia and;
(4)no specific diagnoses were excluded in the studied
cohort.
Search
The main search terms were “conjugated hyperbilirubine-
mia” or “cholestatic jaundice” and “neonates” or “infants.”
The following filters were used: human. No language filter
was used; however, when abstract review was required,
citations without English abstracts were eliminated. The
searches were performed independently by two of the
authors and the results were compared.
Study selection
Initial evaluation of each article was performed by au-
thor LEG and then reviewed by author MTD. Differ-
ences in judgment were resolved first by consensus; ties
were adjudicated by the third author (SCA).
Data collection
For each selected study, the following information was
recorded: number of patients, age range of patients, and
country of origin. The categorical and specific etiologies
of conjugated hyperbilirubinemia and the number of
patients classified into each group for all selected stud-
ies were recorded. The categories of disease included
EHBA, INH, total parenteral nutrition (TPN)—associated
cholestasis, Alagille’s syndrome, alpha 1-antitrypsin defi-
ciency, cystic fibrosis (CF), infection, hypopituitarism/
hypothyroidism, progressive familial intrahepatic cholesta-
sis (PFIC), perinatal hypoxia/ischemia, interlobular bile
duct paucity, inspissated bile syndrome, choledochal cysts,
hemolysis, metabolic diseases, and others. Within the cat-
egories of infection and metabolic diseases, specific etiolo-
gies were catalogued based on the data provided in each
study. Data collection was reviewed by the second author
(MTD).
Synthesis of results
Results from all of the studies were pooled to provide
rate estimates of categorical and specific etiologies of
cholestasis. Rate estimates for etiologic categories were
calculated from the number of subjects used in the en-
tire review. Rate estimates for specific infectious and
metabolic etiologies used the total number of subjects
reported with specific infectious and metabolic disorders
as the denominator.
Sources of bias across studies
Variability in diagnostic evaluations and the potential for
overestimation of INH represent possible sources for
bias. The identification of multiple etiologies in individ-
ual patients as well as inconsistencies and vagaries in no-
menclature were potential sources of error when studies
were combined. In some cases, delayed clinical presenta-
tion may have affected diagnostic accuracy.
Results and discussion
Study selection
The results of the literature search are shown in the
Fig. 1. Searches of Medline and EMBASE databases
yielded 193 references. An additional 44 citations were
found by extensively searching the bibliographies of se-
lected articles. From the 237 studies identified, 180 stud-
ies were excluded after a cursory review of the title,
abstract, and, when necessary, the results section. The
full text of the remaining 57 articles was reviewed in de-
tail. Forty of the remaining studies were excluded: 11 re-
ports failed to report specific diagnoses; 6 reports had
inclusion criteria that were too narrow; 6 reports in-
cluded patients without conjugated hyperbilirubinemia;
6 reports were not case series or cohort studies; 5 reports
had subjects with previously identified disease processes; 2
failed to include a detailed clinical evaluation; 1 each had
vague inclusion criteria, non-consecutive patients, in-
cluded the same patient population from another selected
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study, or had a sample size of less than 10. The remaining
17 studies comprise this review [1, 4–20].
Study characteristics and outcomes
The 17 studies that met the inclusion criteria are pre-
sented in Table 1 [1, 4–20]. These reports ranged in size
from 20 to 249 participants and represented a world-
wide sample (United States, Turkey, United Kingdom,
Bangladesh, China, Sweden, South Africa, Iran, Nigeria,
Australia, India, and Thailand). Children were drawn
from single centers in 15 studies and entire regions in 2
studies. The number of patients included in this review
is 1692.
The etiologies of infantile conjugated hyperbilirubine-
mia, by study, are shown in Table 2. Humphrey et. al re-
ported 15 subjects with “prematurity, sepsis and
parenteral nutrition” [18]. These subjects were grouped
into the “other” category because a single etiology could
not be chosen. Tolia et. al. excluded subjects whose cho-
lestatic jaundice resolved after 6 months and thus did
not undergo a full diagnostic work-up [12]. Johnson et.
al excluded nine subjects with biliary tract obstruction
but “were either too ill or parents declined ex-lap to de-
fine nature” and, eight undiagnosed subjects who did
not return for re-evalaution [16]. All 17 of these patients
were included in the present review and categorized as
“other”. Spivak excluded five subjects who “did not have
scans because they either were too ill to transport or
died before the study” [14]. These subjects were included
and classified as “other.” Motala et. al excluded TPN- as-
sociated cholestasis and Danks et. al excluded subjects
with choledochal cysts [15, 20]. Attempts to contact
these authors were unsuccessful. Despite exclusions of
specific diagnoses, these studies were retained.
Synthesis of results
The etiologies of conjugated hyperbilirubinemia in







Records screened: n = 237 Records excluded: n = 180
Full-text articles assessed: n = 57 Full-text articles excluded: n = 40
Studies included in systematic 
review: n = 17
Fig. 1 Summary of Literature Search
Table 1 Summary of included studies
Study citation # of
patients




Hitch et. al [19] 28 1.5–17 weeks United States
Tolia et. al [12] 20 2–28 weeks United States
Tiker et. al [13] 42 0–4 weeks Turkey
Humphrey et. al
[18]
90 1–21 weeks United
Kingdom
Bazlul Karim et. al
[7]
62 4–92 weeks Bangladesh
Jiang et. al [11] 50 4–24 weeks China
Fischler et. al [10] 85 1–39 weeks Sweden
Spivak et. al [14] 33 Not recorded United States
Motala et. al [15] 145 Not recorded South Africa
Ipek et. al [17] 92 0–10 weeks Turkey
Rafeey et. al [4] 122 2–17 weeks Iran
Johnson et. al [16] 101 0–24 weeks Nigeria
Stormon et. al [9] 205 0–24 weeks Australia
Mowat et. al [8] 137 0–12 weeks England
Yachha et. al [6] 60 8–24 weeks India
Aanpreung et. al [5] 249 0–12 weeks Thailand
Danks et. al [20] 171 0–6 weeks Australia
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N/% N/% N/% N/% N/% N/% N/% N/%
Hitch et. al [18] 9 7 6 - 1 1 - -
32.14% 25.00% 21.43% 3.57% 3.57%
Tolia et. al [11] 6 2 6 - 2 1 - 2
30.00% 10.00% 30.00% 10.00% 5.00% 10.00%
Tiker et. al [12] 1 2 3 - - - - 16
2.38% 4.76% 7.14% 38.10%
Humphrey et. al [17] 30 22 - 4 2 4 3 2
33.33% 24.44% 4.44% 2.22% 4.44% 3.33% 2.22%
Bazlul Karim et. al [5] 16 15 - - 1 1 - 22
25.81% 24.19% 1.61% 1.61% 35.48%
Jiang et. al [10] 23 22 - - - - - -
46.00% 44.00%
Fischler et. al [9] 30 15 - 3 - 11 1 7
35.29% 17.65% 3.53% 12.94% 1.18% 8.24%
Spivak et. al [13] 7 6 5 - 6 - - 1
21.21% 18.18% 15.15% 18.18% 3.03%
Motala et. al [14] 41 52 Excludeds♦ - - 6 1 35
28.28% 35.86% 4.14% 0.69% 24.14%
Ipek et. al [16] 4 7 8 - 2 - - 9
4.35% 7.61% 8.70% 2.17% 9.78%
Rafeey et. al [2] 30 44 - 1 13 - 1 4
24.59% 36.07% 0.82% 10.66% 0.82% 3.28%
Johnson et. al [15] 31 33 - - - 1 - 12
30.69% 32.67% 0.99% 11.88%
Stormon et. al [7] 34 18 35 6 1 13 7 23
16.59% 8.78% 17.07% 2.93% 0.49% 6.34% 3.41% 11.22%
Mowat et. al [6] 32 61 - - 1 24 2 9
23.36% 44.53% 0.73% 17.52% 1.46% 6.57%
Yachha et. al [4] 33 7 - - 2 - - 5
55.00% 11.67% 3.33% 8.33%
Aanpreung et. al [3] 56 58 46 2 - - - 25
22.49% 23.29% 18.47% 0.80% 10.04%
Danks et. al [19] 55 69 - - 11 8 - 22
32.16% 40.35% 6.43% 4.68% 12.87%
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specific disease entity, where adequate data existed. The
categorical etiologies are shown in Table 3. Of the 1692
subjects who comprise this review, INH was reported in
440 (26.0 %); EHBA occurred in 438 subjects (25.9 %)
and infection was identified in 194 subjects (11.5 %).
Less common categorical causes of infantile cholestatic
jaundice included: TPN -associated cholestasis (109 sub-
jects, 6.4 %), metabolic disease (74 subjects, 4.4 %),
alpha-1 antitrypsin deficiency (70 subjects, 4.1 %), peri-
natal hypoxia/ischemia (62 subjects, 3.7 %), interlobular
bile duct paucity (42 subjects, 2.5 %), choledochal cyst
(36 subjects, 2.1 %), hypopituitarism/hypothyroidism (33















N/% N/% N/% N/% N/% N/% N/% N/%
Hitch et. al [18] - - - - 1 3
3.57% 10.71%
Tolia et. al [11] - - - - - - - 1
5.00%
Tiker et. al [12] 1 - 7 - - 5 1 6
2.38% 16.67% 11.90% 2.38% 14.29%
Humphrey et. al [17] 2 2 - 1 1 - - 17
2.22% 2.22% 1.11% 1.11% 18.89%
Bazlul Karim et. al [5] 3 - - - 4 - - -
4.84% 6.45%
Jiang et. al [10] - 1 - - 2 - 2 -
2.00% 4.00% 4.00%
Fischler et. al [9] 1 11 - - - - - 6
1.18% 12.94% 7.06%
Spivak et. al [13] - - - 3 - - - 5
9.09% 15.15%
Motala et. al [14] - - - - 5 - 5 -
3.45% 3.45%
Ipek et. al [16] 4 - 28 6 - 15 6 3
4.35% 30.43% 6.52% 16.30% 6.52% 3.26%
Rafeey et. al [2] - 1 - - 2 - 25 1
0.82% 1.64% 20.49% 0.82%
Johnson et. al [15] - - - 3 2 - - 19
2.97% 1.98% 18.81%
Stormon et. al [7] 10 2 21 9 3 - 17 6
4.88% 0.98% 10.24% 4.39% 1.46% 8.29% 2.93%
Mowat et. al [6] - - - - 2 - 2 4
1.46% 1.46% 2.92%
Yachha et. al [4] - - - - - - 2 11
3.33% 18.33%
Aanpreung et. al [3] 12 - 6 1 14 4 8 17
4.82% 2.41% 0.40% 5.62% 1.61% 3.21% 6.83%
Danks et. al [19] - - - - Excluded✧ - 6 -
3.51%
a See text for complete list and count of “other” diagnoses
♦TPN associated cholestasis was excluded from Motala et. al. See text for further detail.
✧Choledochal cysts were excluded from Danks et. al. See text for further detail
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subjects, 2.0 %), hemolysis (24 subjects, 1.4 %), inspissated
bile syndrome (23 subjects, 1.4 %), PFIC (17 subjects,
1.0 %), Alagille syndrome (16 subjects, 1.0 %), and cystic fi-
brosis (15 subjects, 0.9 %). Diagnoses categorized as “other”
occurred in 99 subjects (5.9 %) and are listed in Table 4.
The specific infectious etiologies associated with in-
fantile conjugated hyperbilirubinemia are shown in
Table 5. Among the 194 subjects with an infectious eti-
ology, CMV was identified in 65 subjects (33.5 %). Sepsis
(24.7 %), congenital syphilis (10.8 %), and E. coli UTI
(9.8 %) were the next most common entities identified.
Of the patients with sepsis, bacterial and viral etiologies
were identified in 11: Pseudomonas aeruginosa, Staphylo-
coccus species, Klebsiella species, E. coli, cocksackie B, and
parainfluenza type 3 [16, 17, 20].
Metabolic disorders associated with infantile conju-
gated hyperbilirubinemia are shown in Table 6. Among
the 74 subjects reported to have a metabolic disease, ga-
lactosemia was identified in 27 subjects (36.5 %). Thir-
teen subjects (17.6 %) had undefined metabolic disease.
Glycogen storage disease, tyrosinemia, and iron storage
disease accounted for 9.5, 8.1, and 8.1 % respectively.
Risk of bias across studies
Study sizes ranged from 20 to 249 subjects; the largest
study accounted for 14.7 % of the total sample reducing
the risk of selection bias in the pooled results. The sub-
jects represented 12 countries and five continents; 2
Table 3 Summary of etiologies of conjugated hyperbilirubinemia
in infancy by disease category
Total number % of total
Idiopathic Neonatal Hepatitis (INH) 440 26.00 %
Extrahepatic Biliary Atresia (EHBA) 438 25.89 %
Infection 194 11.47 %
TPN associated cholestasis 109 6.44 %
Metabolic disease 74 4.37 %
Alpha-1 Antitrypsin deficiency 70 4.14 %
Perinatal hypoxia/ischemia 62 3.66 %
Interlobular bile duct paucity 42 2.48 %
Choledochal cyst 36 2.13 %
Hypopituitarism/hypothyroidism 33 1.95 %
Hemolysis 24 1.42 %




Alagille syndrome 16 0.95 %
Cystic Fibrosis 15 0.89 %
Other a 99 5.85 %
Total 1692 100.00 %
a See text for complete list and count of “other” diagnoses
Table 4 Other etiologies of conjugated hyperbilirubinemia
Total number % of total
Icterus of unknown cause 19 19.19 %
Trisomy 21 16 16.16 %
Cholestasis of prematurity 15 15.15 %
Sujcts too ill to transport to scanner,
died before the study, or parents
declined diagnostic procedures
15 15.15 %
Undiagnosed subjects who did not
return for follow-up
8 8.08 %
Neonatal systemic lupus erythematosus 5 5.05 %
Mitochondrial dysfunction 3 3.03 %
Neonatal sclerosing cholangitis 2 2.02 %
Common bile duct (CBD) stones 2 2.02 %
Congenital hepatic fibrosis 1 1.01 %
Portal venous thrombosis 1 1.01 %
Aagenae’s syndrome 1 1.01 %
Carbohydrate deficient glycoprotein 1 1.01 %
Familial hemophagocytic lymphohistiocytosis 1 1.01 %
Annular pancreas 1 1.01 %
Arthrogryposis syndrome 1 1.01 %
Histiocytosis X 1 1.01 %
Stenosis of the choledochojejunal junction 1 1.01 %
Hydrocephalus 1 1.01 %
Cleidocranial dysostosis 1 1.01 %
Cardiomyopathy/hydrops fetalis 1 1.01 %
Renal tubular acidosis 1 1.01 %
Spontaneous perforation of the CBD 1 1.01 %
Total 99 100.00 %
Table 5 Infectious causes of conjugated hyperbilirubinemia in
infancy
Total number % of total
CMV 65 33.51 %
Sepsis a 48 24.74 %
Congenital Syphilis 21 10.82 %
E. coli UTI 19 9.79 %
Rubella 12 6.19 %
Toxoplasmosis 7 3.61 %
Hepatitis B 3 1.55 %
Herpes Simplex 2 1.03 %
Other b 17 8.76 %
Total 194 100.00 %
a See text for explanation of sepsis
b EBV, cholangiolitis, Klebsiella UTI, Enterovirus (3), Tuberculosis,
hemophagocytic syndrome, HIV (3), Candidemia (3), Pneumonia (2),
unknown (2)
Gottesman et al. BMC Pediatrics  (2015) 15:192 Page 6 of 8
studies drew patients from entire regions and the remaining
studies each represented one clinical site. Eight of the cen-
ters were referral sites. Nine of the studies were prospective
and eight were retrospective. Five studies focused on spe-
cific diagnostic techniques to differentiate biliary atresia
from neonatal hepatitis.
Tiker et. al and Ipek et. al studied subjects admitted to
neonatal intensive care units [13, 17]. In Tiker et. al,
etiologic prevalence rates differed from those of the
other studies presumably due to the study’s narrow in-
clusion of newborns less than 1 month of age [13].
Vagaries associated with terminology, e.g., “neonatal
hepatitis,” “idiopathic neonatal hepatitis,” and “cholestatic
jaundice,” were encountered in multiple studies [6, 12, 13].
For the purpose of this review, patients were categorized
into idiopathic neonatal hepatitis if no underlying etiology
was found. Yachha et. al classified seven subjects as neo-
natal hepatitis and 11 as neonatal cholestatic syndrome of
indeterminate etiology; [6] neonatal hepatitis subjects were
re-classified into INH and the rest were re-classified as
“other” in this review.
Concurrent diagnoses were also a source of bias across
studies. Ipek et. al categorized each subject under a sin-
gle etiology but reported that “the majority of infants
(80.4 %) had concomitant clinical disorders that might
have contributed to the development of conjugated
hyperbilirubinemia.” [17] Aanpreung et. al cited 46 sub-
jects with TPN—associated cholestasis but reported that
41 of these infants were premature and “TPN was not a
single cause since there could be other causes such as
hypoxia, sepsis, and drug-induced” [5]. These 46 subjects
were categorized under TPN- associated cholestasis
since the author chose to identify them as such. Similarly,
Humphrey et. al reported 15 subjects with “prematurity
with sepsis and parenteral nutrition” [18]. Since this incor-
porated multiple diagnoses without a single diagnosis fa-
vored, these subjects were classified as “other.” Tolia et. al
categorized one subject as both neonatal hepatitis and
TPN associated cholestasis [12]. This subject was re-
categorized under TPN associated cholestasis.
Although Downs syndrome is not a proven cause of
conjugated hyperbilirubinemia, it was cited as the eti-
ology in 4 studies [5, 8, 10, 13]. In these cases, if mul-
tiple diagnoses were identified, the most probable cause
was used to categorize the subject; if Downs syndrome
was the sole diagnosis, the subject was categorized as
“other.” Tiker et. al identified Downs syndrome as the
etiology in three subjects, 2 of whom had concurrent
diagnoses of hypothyroidism and idiopathic neonatal
hepatitis [13]. These 2 subjects were assigned to categor-
ies based on the concurrent diagnosis. Fischler et. al
cited Downs syndrome as a sole diagnosis in one subject
[10]. Mowat et. al identified “chromosomal trisomy” as
“possibly but not definitely causative” of neonatal hepa-
titis in four subjects who did not have evidence of other
etiologies [8]. These four subjects were classified as
“other.” Aanpreung et. al cited Downs syndrome as the
sole etiology in 11 subjects [5].
Limitations
Infantile conjugated hyperbilirubinemia presents with
persistent jaundice as part of a clinical constellation that
may include other symptoms based on the underlying
etiology. The differential diagnosis is broad and requires
timely evaluation [2]. The data presented in this review
suggest that INH, EHBA, and infection (with CMV be-
ing the most common infection) account for 63.36 % of
all cases of infants presenting with elevated serum con-
centrations of conjugated bilirubin.
The diagnostic evaluation should be guided by symp-
tomatology and may include various imaging studies and
serologic, hematologic, and urine investigations for vari-
ous infections and endocrinopathies, as well as genetic
testing for inborn errors of metabolism. While the de-
finitive diagnosis of EHBA requires a percutaneous liver
biopsy, ongoing research is investigating less invasive
methods of differentiating EHBA from other etiologies
of infantile conjugated hyperbilirubinemia [1].
Inconsistency of the diagnostic approach is a major
limitation of this review. While there are general guide-
lines directing the evaluation of an infant with conju-
gated hyperbilirubinemia, reports published prior to
establishment of these guidelines are included in the
present review [1]. Moreover, diagnostic practices vary
by country and multiple studies focused on the ability of
a specific radiologic test to differentiate EHBA from
other causes of conjugated hyperbilirubinemia. Together,
Table 6 Metabolic disease as causes of conjugated
hyperbilirubinemia in infancy
Total number % of total
Galactosemia 27 36.49 %
Glycogen Storage Disease 7 9.46 %
Tyrosinemia 6 8.11 %
Iron Storage Disease 6 8.11 %
Niemann-Pick 4 5.41 %
Zellweger 3 4.05 %
Fat storage disease 2 2.70 %
Hereditary fructose intolerance 2 2.70 %
HMG CoA lyase deficiency 1 1.35 %
Citrullinemia 1 1.35 %
Methyl-malonic acidemia 1 1.35 %
Gaucher disease 1 1.35 %
Unknown* 13 17.57 %
Total 74 100.00 %
*See text for complete list and count of “unknown” diagnoses
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these conditions may introduce inherent disparities in
evaluation and may contribute to bias among these stud-
ies [11, 12, 14, 18, 19].
Variability in sample populations is also a potential
source of bias. While 12 countries and 5 continents are
represented, there is no data from Eastern Europe or
South America. Disorders that may be uniquely preva-
lent in these areas may be underrepresented. Finally,
summary data that includes subjects from all over the
world may be less relevant to any specific country given
the uneven distribution of etiologies between developed
and developing countries as well as diseases endemic to
the East and West.
Finally, the use of the category of INH to include all
idiopathic cases of infantile conjugated hyperbilirubine-
mia is a potential source of bias in this review [6, 10–14,
16, 18, 19]. While Ipek et. al defined INH as conjugated
hyperbilirubinemia that persists beyond 3 months with-
out another identifiable cause [17], multiple studies did
not specifically use the term INH or provide a definition.
Conclusions
The etiologies of infantile conjugated hyperbilirubinemia
are numerous. Because of the consequences of untimely
correction of EHBA as well as the potential conse-
quences of untreated galactosemia, hypothyroidism and
other etiologies associated with this problem, clinical
evaluation needs to be prompt, focused, and complete.
While specific symptoms may narrow the diagnostic
possibilities, a complete history and physical examin-
ation, diagnostic imaging and laboratory investigations
directed at the more common etiologies is required to
make a prompt, definitive diagnosis. This systematic re-
view provides evidence to direct the investigation of an
infant with conjugated hyperbilirubinemia.
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